Table 1.
Baseline patients’ characteristics in the whole study group and separately according to Tp53 (wild type versus mutated)
| Whole (n = 30) | Next Generation Sequencing | P | |||
|---|---|---|---|---|---|
|
| |||||
| Tp53 Wild (n = 20) | Tp53 Mutated (n = 10) | ||||
| Age, years (IQR) | 77 (63-83) | 78 (62-84) | 74 (67-80) | 0.35 | |
| Male gender n. (%) | 17 (56.7%) | 10 (50%) | 7 (70%) | 0.44 | |
| White Blood Cell count (×103) | 3.71 (2.63-5.01) | 4.08 (2.57-5.00) | 4.60 (2.96-6.59) | 0.59 | |
| Platelet count (×103) | 275 (111-429) | 275 (160-451) | 202 (81-300) | 0.31 | |
| Race n. (%) | Caucasian | 29 (96.7%) | 20 (100%) | 9 (90%) | 0.35 |
| Asian | 1 (3.3%) | 0 (0%) | 1 (10%) | ||
| Charlson comorbidity index n. (%) | |||||
| 0 | 23 (76.7%) | 16 (80.0%) | 7 (70%) | ||
| 1 | 3 (10.0%) | 2 (10.0%) | 1 (10%) | ||
| 2 | 1 (3.3%) | 0 (0%) | 1 (10%) | 0.28 | |
| 3 | 2 (6.7%) | 2 (10.0%) | 0 (0%) | ||
| 4 | 1 (3.3%) | 0 (%) | 1 (10%) | ||
| Baseline karyotype n. (%) | |||||
| Isolated del 5q | 24 (80.0%) | 20 (100%) | 4 (40%) | ||
| Del5q and 1 abnormality | 2 (6.7%) | 0 (0%) | 2 (20%) | 0.002 | |
| Complex (3 abnormalities) | 1 (3.3%) | 0 (0%) | 1 (10%) | ||
| Complex >3 abnormalities | 3 (10.0%) | 0 (0%) | 3 (30%) | ||
| BM blasts (%) | 3 (1-4) | 3 (1-4) | 3 (1-8) | 0.40 | |
| BM blasts n. (%) | <5% | 24 (80.0%) | 18 (90%) | 6 (60%) | 0.14 |
| ≥5% | 6 (20.0%) | 2 (10%) | 4 (40%) | ||
| Hemoglobin (g/dL) | 9.1±1.2 | 9.2±1.0 | 9.0±1.6 | 0.74 | |
| WHO subgroup n. (%) | |||||
| MDS-MLD | 2 (6.7%) | 0 (0%) | 2 (20%) | ||
| MDS with del(5q) | 22 (73.3%) | 18 (90%) | 4 (40%) | 0.01 | |
| MDS-EB-1/EB-2 | 6 (20.0%) | 2 (10%) | 4 (40%) | ||
| IPSS n. (%) | Low | 13 (43.3%) | 11 (55.0%) | 2 (20%) | |
| Intermediate-1 | 14 (46.7%) | 9 (45.0%) | 5 (50%) | 0.048 | |
| Intermediate-2 | 2 (6.7%) | 0 (0%) | 2 (20%) | ||
| High | 1 (3.3%) | 0 (0%) | 1 (10%) | ||
| IPSS revised n. (%) | Very Low | 4 (13.3%) | 3 (15%) | 1 (10%) | |
| Low | 13 (43.4%) | 11 (55%) | 2 (20%) | ||
| Intermed | 10 (33.3%) | 6 (30%) | 4 (40%) | 0.042 | |
| Very High | 3 (10.0%) | 0 (0%) | 3 (30%) | ||
| % of BM progenitor cells expressing Tp53 with intensity score 3+ in HIC (%) | 1.34 (0.71-3.70) | 0.9 (0.5-3.4) | 2.6 (0.8-12.1) | 0.12 | |
| % of BM progenitor cells expressing Tp53 with intensity score 3+ in IHC | |||||
| ≥1% | 16 (55.2%) | 9 (47.4%) | 7 (70%) | 0.43 | |
| <1% | 13 (44.8%) | 10 (52.6%) | 3 (30%) | ||
IQR, interquartile range; BM, bone marrow; WHO, World Health Organization; IPSS, International Prognostic Scoring System; MLD, multilineage dysplasia; EB, excess blasts.